Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results.
暂无分享,去创建一个
E. Baudin | Z. Tsuchihashi | G. Kaltsas | D. Castellano | E. Wolin | S. Saletan | D. Gross | J. Yao | J. Lebrec | J. Klimovsky